---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-029038"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T10:58:18.895587+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# ANI Pharmaceuticals amends bylaws to adopt universal proxy rules, update DGCL provisions, add forum selection clause

## Summary
- Board approved Second Amended and Restated Bylaws effective Feb 28, 2023, incorporating universal proxy rules and recent DGCL amendments.
- Quorum for stockholder meetings (other than Board-called) changed to majority of voting power; stockholder list requirement removed.
- Enhanced disclosure and procedural requirements for stockholder proposals and director nominations, including universal proxy compliance.
- Indemnification provisions updated with mandatory advancement of expenses subject to Board consent; forum selection clause added for Delaware and federal courts.

## SEC filing metadata
- accession: 0001104659-23-029038
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000110465923029038/0001104659-23-029038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000110465923029038/tm238560d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-029038
- JSON: https://secwatch.observer/filing/0001104659-23-029038.json
- Plain text: https://secwatch.observer/filing/0001104659-23-029038.txt

## Key facts
- Governance Changes
  ANI PHARMACEUTICALS INC: Board adopted Second Amended and Restated Bylaws with clarifying amendments, updates for universal proxy rules and DGCL, including changes to quorum requirements, stockholder proposal procedures, director nomination procedures, indemnification provisions, and a forum selection clause (effective 2023-02-28).
  - Change: bylaw amendment
  - Effective: 2023-02-28
  source text: On February 28, 2023, the Board of Directors (the “Board”) of ANI Pharmaceuticals, Inc. (the “Company”) approved the Second Amended and Restated Bylaws of the Company (the “Bylaws”), which became effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1023024/000110465923029038/0001104659-23-029038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.